Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:0
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [31] HIGH-RISK NMIBC (NON-MUSCLE INVASIVE BLADDER CANCER): PROGNOSTIC VALUE OF CIRCULATING TUMOR CELLS
    De Berardinis, Ettore
    Busetto, Gian Maria
    Petracce, Arianna
    Nicolazzo, Chiara
    Gazzaniga, Paola
    Gentile, Vincenzo
    JOURNAL OF UROLOGY, 2011, 185 (04): : E205 - E206
  • [32] New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
    Asimakopoulos, Anastasios D.
    Kochergin, Maxim
    Colalillo, Gaia
    Fahmy, Omar
    Hassan, Fahmy
    Renninger, Markus
    Gallioli, Andrea
    Gavrilov, Pavel
    Gakis, Georgios
    BLADDER CANCER, 2023, 9 (03) : 237 - 251
  • [33] New immunotherapies for high-risk non-muscle invasive bladder cancer: Current state and future perspectives
    Gomez del Canizo, C.
    Rodriguez-Izquierdo Jimenez, M.
    Pena Vallejo, E.
    Duarte Ojeda, J. M.
    de la Rosa Kehrman, F.
    Rodriguez Antolin, A.
    Guerrero Ramos, F.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (09): : 574 - 585
  • [34] The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article
    Kodera, Ahmed
    Mohammed, Mahmoud
    Lim, Paul
    Abdalla, Omer
    Elhadi, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [35] The long term outcome of high risk non-muscle invasive bladder cancer
    Thomas, F.
    Rubin, N.
    Goepel, J.
    Abbod, M. F.
    Rosario, D.
    Catto, J. W. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E965 - U26
  • [36] Value of Fluorescence Cystoscopy in High Risk Non-muscle Invasive Bladder Cancer
    Mayr, Roman
    Burger, Maximilian
    CURRENT UROLOGY REPORTS, 2013, 14 (02) : 90 - 93
  • [37] Value of Fluorescence Cystoscopy in High Risk Non-muscle Invasive Bladder Cancer
    Roman Mayr
    Maximilian Burger
    Current Urology Reports, 2013, 14 : 90 - 93
  • [38] Management of high risk non-muscle invasive bladder cancer: is re-resection always essential?
    Bangash, H.
    Lozinskiy, M.
    Hayne, D.
    BJU INTERNATIONAL, 2017, 119 : 18 - 18
  • [39] Alternatives for cytology in the management of non-muscle invasive bladder cancer
    Amiel G.E.
    Shu T.
    Lerner S.P.
    Current Treatment Options in Oncology, 2004, 5 (5) : 377 - 389
  • [40] Novel approaches to the management of non-muscle invasive bladder cancer
    Kamat, Ashish M.
    CLINICAL CANCER RESEARCH, 2024, 30 (10)